News | July 06, 2022
Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The vaccine is under FDA review
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
It is a two dose vaccine to be administered intramuscularly at 28 days apart
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Subscribe To Our Newsletter & Stay Updated
